UTHR · NASDAQ
United Therapeutics Corporation
$608.49 +6.74 (+1.12%)
Company overview
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance exercise ability in PAH patients.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $26.1B
- Employees
- 1,305
- Headquarters
- Silver Spring, MD
- Website
- unither.com
- CEO
- Martine A. Rothblatt
- Listed
- June 17, 1999
- P/E
- 20.79
- Dividend yield
- 0.00%
Company financials
- Revenue
- $3.2B
- Gross profit
- $2.7B
- Operating income
- $1.4B
- EBITDA
- $1.7B
- Net income
- $1.3B
- EPS
- $29.27
- Total assets
- $6.7B
- Total debt
- $0.00
- Gross margin
- 86.58%
- Net margin
- 40.61%
- Earnings yield
- 4.81%
Showing FY 2025
UTHR
1D
NASDAQ
O596.14H606.72L596.14C601.75+5.62 (+0.94%)Vol464.94K
News